- Home
- RCEL vs ADAG Comparison
RCEL vs ADAG Comparison
Compare RCEL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCEL
- ADAG
- Stock Information
- Founded
- RCEL N/A
- ADAG 2011
- Country
- RCEL United States
- ADAG China
- Employees
- RCEL N/A
- ADAG N/A
- Industry
- RCEL Medical/Dental Instruments
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- RCEL Health Care
- ADAG Health Care
- Exchange
- RCEL Nasdaq
- ADAG Nasdaq
- Market Cap
- RCEL 113.7M
- ADAG 110.8M
- IPO Year
- RCEL N/A
- ADAG 2021
- Fundamental
- Price
- RCEL $4.56
- ADAG $2.24
- Analyst Decision
- RCEL Strong Buy
- ADAG Strong Buy
- Analyst Count
- RCEL 4
- ADAG 2
- Target Price
- RCEL $13.75
- ADAG $7.00
- AVG Volume (30 Days)
- RCEL 282.4K
- ADAG 140.2K
- Earning Date
- RCEL 11-06-2025
- ADAG 08-12-2025
- Dividend Yield
- RCEL N/A
- ADAG N/A
- EPS Growth
- RCEL N/A
- ADAG N/A
- EPS
- RCEL N/A
- ADAG N/A
- Revenue
- RCEL $74,884,000.00
- ADAG $103,204.00
- Revenue This Year
- RCEL $28.23
- ADAG $9,789.15
- Revenue Next Year
- RCEL $35.24
- ADAG $29.92
- P/E Ratio
- RCEL N/A
- ADAG N/A
- Revenue Growth
- RCEL 38.32
- ADAG N/A
- 52 Week Low
- RCEL $3.60
- ADAG $1.33
- 52 Week High
- RCEL $14.16
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- RCEL 46.58
- ADAG 52.00
- Support Level
- RCEL $4.12
- ADAG $2.24
- Resistance Level
- RCEL $4.44
- ADAG $2.49
- Average True Range (ATR)
- RCEL 0.25
- ADAG 0.22
- MACD
- RCEL 0.03
- ADAG 0.00
- Stochastic Oscillator
- RCEL 50.00
- ADAG 14.81
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.